​

ADC Therapeutics (ADCT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

ADC Therapeutics Revenue Highlights

Latest Revenue (Y)

$69.28M

Latest Revenue (Q)

$17.41M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

ADC Therapeutics Revenue by Period

ADC Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$69.28M-0.40%
2023-12-31$69.56M-66.86%
2022-12-31$209.91M518.89%
2021-12-31$33.92M100.00%
2020-12-31--100.00%
2019-12-31$2.34M105.26%
2018-12-31$1.14M-36.77%
2017-12-31$1.80M-

ADC Therapeutics generated $69.28M in revenue during NA 2024, up -0.40% compared to the previous quarter, and up 2960.68% compared to the same period a year ago.

ADC Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$17.41M-3.56%
2024-03-31$18.05M7.52%
2023-12-31$16.79M15.85%
2023-09-30$14.49M-24.84%
2023-06-30$19.28M1.53%
2023-03-31$18.99M-72.79%
2022-12-31$69.80M-8.55%
2022-09-30$76.32M341.39%
2022-06-30$17.29M-62.81%
2022-03-31$46.50M173.36%
2021-12-31$17.01M29.38%
2021-09-30$13.15M249.65%
2021-06-30$3.76M100.00%
2021-03-31--100.00%
2020-12-31$51.90M100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30--100.00%
2019-06-30$1.96M67.69%
2019-03-31$1.17M354.37%
2018-12-31$257.50K-
2018-09-30$257.50K-17.60%
2018-06-30$312.50K-
2018-03-31$312.50K-

ADC Therapeutics generated $17.41M in revenue during Q2 2024, up -3.56% compared to the previous quarter, and up 91.67% compared to the same period a year ago.

ADC Therapeutics Revenue Breakdown

ADC Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21
Product$69.28M$69.06M--
Royalty Revenue$1.56M$498.00K--
License Revenues----
Contract Revenue--$135.00M-
Product Revenue--$74.91M$33.92M

ADC Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (97.80%), and Royalty Revenue (2.20%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Dec 23Jun 23Mar 23Sep 22Jun 22Mar 22
Product$33.42M$18.02M$17.85M------
Royalty Revenue$904.00K$448.00K$205.00K$373.00K$86.00K$39.00K---
License Revenue------$55.00M-$30.00M
Product Revenue, Net----$19.20M$18.95M$21.32M$17.29M$16.50M

ADC Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (97.37%), and Royalty Revenue (2.63%).

ADC Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23
EMEA$1.56M$498.00K
UNITED STATES$69.28M$69.06M
JAPAN--

ADC Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (97.80%), and EMEA (2.20%).

Quarterly Revenue by Country

CountryDec 24Sep 24Mar 24Dec 23Jun 23Mar 23
UNITED STATES$33.42M$18.02M$17.85M$30.91M$19.20M$18.95M
EMEA$904.00K$448.00K$205.00K$373.00K$86.00K$39.00K
JAPAN------

ADC Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (97.37%), and EMEA (2.63%).

ADC Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RAREUltragenyx Pharmaceutical$560.23M$147.03M
ARVNArvinas$263.40M$102.40M
ALECAlector$100.56M$15.08M
ADCTADC Therapeutics SA$69.28M$17.41M
KURAKura Oncology$53.88M-
STOKStoke Therapeutics$36.55M$4.89M
AADIAadi Bioscience$25.98M$7.21M
GBIOGeneration Bio$19.89M$4.09M
RNAAvidity Biosciences$10.90M$2.04M
IPSCCentury Therapeutics$6.59M$791.00K
CRNXCrinetics Pharmaceuticals$1.04M-
DSGNDesign Therapeutics--
AKROAkero Therapeutics--
ALVRAlloVir--
ALXOALX Oncology--
BDTXBlack Diamond Therapeutics--
PTGXProtagonist Therapeutics-$4.67M
RVMDRevolution Medicines--
PASGPassage Bio--

ADCT Revenue FAQ

What is ADC Therapeutics’s yearly revenue?

ADC Therapeutics's yearly revenue for 2024 was $69.28M, representing a decrease of -0.40% compared to 2023. The company's yearly revenue for 2023 was $69.56M, representing a decrease of -66.86% compared to 2022. ADCT's yearly revenue for 2022 was $209.91M, representing an increase of 518.89% compared to 2021.

What is ADC Therapeutics’s quarterly revenue?

ADC Therapeutics's quarterly revenue for Q2 2024 was $17.41M, a -3.56% decrease from the previous quarter (Q1 2024), and a -9.71% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $18.05M, a 7.52% increase from the previous quarter (Q4 2023), and a -4.94% decrease year-over-year (Q1 2023). ADCT's quarterly revenue for Q4 2023 was $16.79M, a 15.85% increase from the previous quarter (Q3 2023), and a -75.94% decrease year-over-year (Q4 2022).

What is ADC Therapeutics’s revenue growth rate?

ADC Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -67.00%, and for the last 5 years (2020-2024) was 0%.

What are ADC Therapeutics’s revenue streams?

ADC Therapeutics's revenue streams in c 24 are Product, and Royalty Revenue. Product generated $69.28M in revenue, accounting 97.80% of the company's total revenue, up 0.32% year-over-year. Royalty Revenue generated $1.56M in revenue, accounting 2.20% of the company's total revenue, up 212.65% year-over-year.

What is ADC Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of ADC Therapeutics was Product. This segment made a revenue of $69.28M, representing 97.80% of the company's total revenue.